Published in New England Journal of Medicine · View the paper (DOI)
The two-year progression-free survival rate was 92% on the N-AVD arm compared to 83% on the BV-AVD arm, with fewer side effects and lower mortality rates. The study's results support the use of nivolumab-AVD as a standard treatment for stage 3-4 classic Hodgkin lymphoma.
Coverage from 2 institutions
- Longer-term data from SWOG S1826 trial confirm nivolumab-AVD benefit in Hodgkin lymphoma SWOG Cancer Research Network · Oct 16, 2024 · first to report
- In landmark study, immunotherapy boosts survival of advanced Hodgkin lymphoma University of Rochester Medical Center · Oct 16, 2024